Longeveron Inc.

Healthcare · Biotechnology · United States

Last price 1.67 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 5.32M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer’s disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated...